Castle Biosciences, Inc. (CSTL) dividends
CSTL on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Castle Biosciences, Inc. dividend: key facts
Own Castle Biosciences, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next CSTL dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference12 Nov 2026 · PRNewsWire
FRIENDSWOOD, Texas, Nov. 11, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executi...
- Castle Biosciences Earns 2026 Top Workplaces Awards Recognizing Its People-First Culture12 Nov 2026 · PRNewsWire
Regional honors in Houston, Arizona and Pittsburgh, national healthcare industry recognition and eight Culture Excellence awards bring Castle's 2026 Top Workplaces honors to 13 FRIENDSWOOD, Texas, Nov...
- DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the Test's Ability to Refine Risk Assessment Beyond AJCC Staging11 Nov 2026 · PRNewsWire
SDPA analysis demonstrates DecisionDx-Melanoma can identify higher-risk patients within a traditionally low-risk population with thin melanomas  Dermato-Onco2026 analysis supports the test's ability t...
- Castle Biosciences price target raised to $52 from $44 at BTIG10 Nov 2026 · TheFly
BTIG raised the firmâs price target on Castle Biosciences (CSTL) to $52 from $44 and keeps a Buy rating on the shares following Q3 beat-and-raise. The firm noted that averageâ¦
- Castle Biosciences price target raised to $41 from $39 at Baird9 Nov 2026 · TheFly
Baird analyst Catherine Ramsey Schulte raised the firmâs price target on Castle Biosciences (CSTL) to $41 from $39 and keeps an Outperform rating on the shares. The firm updated itsâ¦
- Castle Biosciences reports Q3 adjusted EPS (13c), consensus (35c)6 Nov 2026 · TheFly
Reports Q3 revenue $102.9M, consensus $92.91M. âOur team delivered another strong quarter, reflecting consistent execution across our portfolio,â said CEO Derek Maetzold. âTissueCypher was a key contr...
- Castle Biosciences raises 2026 revenue view to $385M-$395M from $345M-$355M6 Nov 2026 · TheFly
2026 revenue consensus $374.12M.
- Castle Biosciences price target raised to $40 from $35 at KeyBanc6 Nov 2026 · TheFly
KeyBanc raised the firmâs price target on Castle Biosciences (CSTL) to $40 from $35 and keeps an Overweight rating on the shares. The firm notes the company posted a top-â¦
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.